

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2023/2024 influenza season

as of November 12, 2024

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	2 (0.4%)	5 (0.5%)	5 (0.5%)	0	0	287 (100%)	4 (0.5%)	0	0	0	0	330 (100%)	0	0	0	0	0
Number of viruses tested	507	1,078	1,078	276	276	287	778	316	316	316	316	330	326	194	194	194	194
Number of viruses reported	2,130						3,655						2,090				

Baloxavir was examined by focus reduction assay, rhPCR allelic discrimination and/or PA sequencing.
NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.
Amantadine was examined by M2 sequencing.